Quizartinib also has shown promising activity in relapsed/refractory (RR) acute myeloid leukemia (AML) with FLT3-internal tandem duplication (ITD) in phase 1 and 2 studies [23–26] and is currently being evaluated in phase 3 studies in both newly diagnosed and R/R FLT3-ITD AML (NCT02668653 and NCT02039726, respectively). This evidence concerns the gene FLT3 and acute myeloid leukemia.